Edition:
India

China Biologic Products Holdings Inc (CBPO.OQ)

CBPO.OQ on NASDAQ Stock Exchange Global Select Market

79.67USD
2:29am IST
Change (% chg)

$-1.13 (-1.40%)
Prev Close
$80.80
Open
$80.81
Day's High
$80.81
Day's Low
$79.10
Volume
31,997
Avg. Vol
63,164
52-wk High
$107.32
52-wk Low
$60.09

Latest Key Developments (Source: Significant Developments)

China Biologic Products Holdings says On Feb 3, Board Elected Joseph Chow To Be New Chairman Of Board
Monday, 4 Feb 2019 

Feb 4 (Reuters) - China Biologic Products Holdings Inc ::CHINA BIOLOGIC PRODUCTS HOLDINGS- ON FEB 1, 2019, ZHIJUN TONG INFORMED CO THAT HE WAS RESIGNING FROM HIS POSITIONS AS PRESIDENT AND DIRECTOR OF CO.CHINA BIOLOGIC PRODUCTS HOLDINGS- ON FEB 1, 2019, ZHIJUN TONG INFORMED CO THAT HE WAS RESIGNING FROM HIS POSITIONS AS PRESIDENT AND DIRECTOR OF CO .CHINA BIOLOGIC PRODUCTS HOLDINGS- ON FEB 3, BOARD UNANIMOUSLY ELECTED JOSEPH CHOW TO BE NEW CHAIRMAN OF BOARD IN SUCCESSION TO DAVID HUI LI.CHINA BIOLOGIC PRODUCTS HOLDINGS- DAVID HUI LI CONTINUES TO SERVE AS A DIRECTOR ON THE BOARD - SEC FILING.  Full Article

China Biologic Reiterates Full Year 2018 Financial Forecast
Monday, 7 Jan 2019 

Jan 7 (Reuters) - China Biologic Products Holdings Inc ::CHINA BIOLOGIC REITERATES FULL YEAR 2018 FINANCIAL FORECAST.  Full Article

China Biologic Announces Dismissal Of Lawsuit Filed In Cayman Islands By Former Chairman
Friday, 14 Dec 2018 

Dec 14 (Reuters) - China Biologic Products Holdings Inc ::CHINA BIOLOGIC ANNOUNCES DISMISSAL OF LAWSUIT FILED IN CAYMAN ISLANDS BY FORMER CHAIRMAN.CHINA BIOLOGIC PRODUCTS - GRAND COURT OF CAYMAN ISLANDS DISMISSED LAWSUIT PREVIOUSLY FILED AGAINST CO BY FORMER CHAIRMAN, CEO DAVID (XIAOYING) GAO.  Full Article

David Gao Confirms Lawsuit Against China Biologic Products
Wednesday, 29 Aug 2018 

Aug 29 (Reuters) - David Gao :DAVID GAO CONFIRMS LAWSUIT AGAINST CHINA BIOLOGIC PRODUCTS TO PROTECT SHAREHOLDERS’ BEST INTERESTS.DAVID GAO - CONFIRMED FILED LAWSUIT AGAINST CO RELATED TO PRIVATE PLACEMENT OF SHARES TO SELECT INVESTOR GROUP.  Full Article

China Biologic Responds To Lawsuit Filed In Cayman Islands By Former Chairman
Wednesday, 29 Aug 2018 

Aug 28 (Reuters) - China Biologic Products Holdings Inc ::CHINA BIOLOGIC RESPONDS TO LAWSUIT FILED IN CAYMAN ISLANDS BY FORMER CHAIRMAN.CHINA BIOLOGIC PRODUCTS HOLDINGS - ISSUED STATEMENT IN RESPONSE TO LAWSUIT FILED AGAINST COMPANY IN CAYMAN ISLANDS BY DAVID (XIAOYING) GAO.CHINA BIOLOGIC PRODUCTS HOLDINGS INC - CLOSED 3.8 MILLION SHARES IN PRIVATE PLACEMENT & WILL CLOSE REMAINING IN ACCORDANCE WITH TRANSACTION AGREEMENTS.  Full Article

Investor Group Issues Statement Following China Biologic’s Private Placement Of Shares
Friday, 24 Aug 2018 

Aug 24 (Reuters) - Investor Group::LEADING INVESTOR GROUP ISSUES STATEMENT FOLLOWING CHINA BIOLOGIC’S DILUTIVE PRIVATE PLACEMENT OF SHARES.INVESTOR GROUP SAYS IN RELATION TO CHINA BIOLOGIC'S REJECTION OF ITS PROPOSAL, "WILL EVALUATE ALL OPTIONS, INCLUDING LEGAL ACTION".  Full Article

PW Medtech Group To Purchase 800,000 China Biologic Products Shares For $80.72 Mln
Friday, 24 Aug 2018 

Aug 24 (Reuters) - PW Medtech Group Ltd <1358.HK>::CO TO PURCHASE 800,000 CHINA BIOLOGIC PRODUCTS (CBPO) SHARES, AT A PRICE OF US$100.9 PER CBPO SHARE.AGGREGATE PURCHASE PRICE FOR CBPO SHARES SHALL BE $80.72 MILLION.  Full Article

China Biologic Announces Receipt Of Competing Non-Binding Acquisition Proposal
Tuesday, 21 Aug 2018 

Aug 21 (Reuters) - China Biologic Products Holdings Inc ::CHINA BIOLOGIC ANNOUNCES RECEIPT OF COMPETING NON-BINDING ACQUISITION PROPOSAL.CHINA BIOLOGIC PRODUCTS HOLDINGS INC - BOARD IS REVIEWING AND EVALUATING CONSORTIUM PROPOSAL AND CITIC PROPOSAL AND NO DECISIONS HAVE BEEN MADE.  Full Article

China Biologic Products Q2 Earnings Per Share $0.83
Saturday, 4 Aug 2018 

Aug 3 (Reuters) - China Biologic Products Holdings Inc ::CHINA BIOLOGIC REPORTS FINANCIAL RESULTS FOR THE SECOND QUARTER OF 2018.Q2 ADJUSTED NON-GAAP EARNINGS PER SHARE $1.17.Q2 EARNINGS PER SHARE $0.83.Q2 SALES ROSE 34.8 PERCENT TO $120.4 MILLION.SAYS REVISES FULL YEAR FINANCIAL FORECAST.IS MAKING A DOWNWARD REVISION TO ITS FULL YEAR 2018 FORECAST.EXPECTS FY2018 NON-GAAP ADJUSTED INCOME FROM OPERATIONS TO INCREASE BY 0% TO 2% IN RMB TERMS.CHINA BIOLOGIC PRODUCTS-"Q2 CONTINUED TO BE CHALLENGING DUE TO ONGOING IMPACT OF REGULATORY CHANGES & INTENSIFIED COMPETITION IN CHINA'S HEALTHCARE MARKET".SEES FY2018 NON-GAAP ADJUSTED NET INCOME TO DECREASE BY 2% TO 4% IN RMB TERMS.CHINA BIOLOGIC-2018 FORECAST WAS LOWERED TO ACCOUNT FOR WORSE-THAN-EXPECTED RESULTS FOR H1 2018 AND ONGOING CHALLENGING OUTLOOK IN H2 OF YEAR.CHINA BIOLOGIC PRODUCTS HOLDINGS-FOR H2, EXPECT "REGULATORY HEADWINDS AND MARKET COMPETITIVE DYNAMICS TO PERSIST", WHICH WILL IMPACT GUIDANCE FOR YEAR.  Full Article

China Biologic Says Excluding Financial Results Of Tianxinfu, Q1 Sales To Grow About 2% In RMB
Tuesday, 24 Apr 2018 

April 24 (Reuters) - China Biologic Products Holdings Inc ::CHINA BIOLOGIC PRODUCTS HOLDINGS - EXCLUDING FINANCIAL RESULTS OF TIANXINFU, TOTAL SALES IN Q1 OF 2018 EXPECTED TO GROW ABOUT 2% IN RMB TERMS.CHINA BIOLOGIC PRODUCTS - INCLUDING TIANXINFU'S CONTRIBUTION, TOTAL SALES FOR Q1 2018 IS EXPECTED TO GROW APPROXIMATELY 13% IN RMB TERMS.CHINA BIOLOGIC PRODUCTS HOLDINGS- EXCLUDING TIANXINFU RESULTS, Q1 NON-GAAP ADJUSTED NET INCOME EXPECTED TO DECLINE 12-14% Y-O-Y IN RMB TERMS.CHINA BIOLOGIC - INCLUDING TIANXINFU'S CONTRIBUTION, NON-GAAP ADJUSTED. NET INCOME FOR Q1 2018 IS EXPECTED TO GROW 1% TO 3% YEAR OVER YEAR IN RMB TERMS.CHINA BIOLOGIC - ONGOING REFORM HEADWINDS INITIATED IN 2017 IN CHINA'S HEALTHCARE MARKET FURTHER NEGATIVELY IMPACTED Q1 SALES REVENUE, PROFIT GROWTH.  Full Article

China Biologic rejects $3.9 billion bid from former CEO

China Biologic Products Holdings Inc rejected a $3.9 billion offer from a consortium led by its former chief executive on Friday and said an affiliate of CITIC Capital had also withdrawn a competing bid.